Viral Hemorrhagic Fever Vaccines Pipeline
Pipeline
Several families of viruses can cause hemorrhagic fevers that can affect multiple organ systems, often damaging the overall vascular system and impairing the body’s ability to regulate itself. These symptoms are often accompanied by persistent bleeding. Many of these viruses cause severe, life-threatening disease.
Filoviruses
Bunyavirales
Filoviruses
We use our expertise to produce high quality recombinant protein vaccine candidates to protect against filoviruses. The Company has developed and patented recombinant glycoproteins (GP) from Ebola virus, Sudan virus, and Marburg virus.
These proteins are being developed into both individual vaccines and multivalent filovirus vaccines. Furthermore, under license from the Company, researchers at the University of Hawaii School of Medicine are working to develop a thermal-stable Ebola vaccine suitable for worldwide distribution without a cold chain requirement. Non-human primate studies have confirmed the efficacy of this approach.
Bunyavirales
The order Bunyavirales contains 13 families infect a variety of plants, animals, and insects. Five of these families have a number of important human pathogens that cause mild to severe disease to include encephalitis and hemorrhagic disease. These viruses have tri-segmented, negative sense RNA genomes.
Crimean-Congo hemorrhagic fever virus (CCHFV), is one of the most serious human pathogen. CCHFV is a highly infectious virus, with mortality rates as high as 50%. CCHFV’s natural geographic distribution continues to expand due to its highly pathogenic characteristics and potential to spread through various mechanisms. It is classified as a biosafety level-4 (BSL-4) pathogen and has been recently reclassified as a Category A Priority Pathogen by NIH. This elevated level of priority for CCHFV is due to its notably highly infectious nature and also reports of transmission by aerosol during the treatment of infected patients.
In collaboration with the University of Texas Medical Branch and the University of Cambridge, Hawaii Biotech is currently developing a CCHFV vaccine utilizing our proprietary vaccine production platform.
Filoviruses
Filoviruses
We use our expertise to produce high quality recombinant protein vaccine candidates to protect against filoviruses. The Company has developed and patented recombinant glycoproteins (GP) from Ebola virus, Sudan virus, and Marburg virus.
These proteins are being developed into both individual vaccines and multivalent filovirus vaccines. Furthermore, under license from the Company, researchers at the University of Hawaii School of Medicine are working to develop a thermal-stable Ebola vaccine suitable for worldwide distribution without a cold chain requirement. Non-human primate studies have confirmed the efficacy of this approach.
Bunyavirales
Bunyavirales
The order Bunyavirales contains 13 families infect a variety of plants, animals, and insects. Five of these families have a number of important human pathogens that cause mild to severe disease to include encephalitis and hemorrhagic disease. These viruses have tri-segmented, negative sense RNA genomes.
Crimean-Congo hemorrhagic fever virus (CCHFV), is one of the most serious human pathogen. CCHFV is a highly infectious virus, with mortality rates as high as 50%. CCHFV’s natural geographic distribution continues to expand due to its highly pathogenic characteristics and potential to spread through various mechanisms. It is classified as a biosafety level-4 (BSL-4) pathogen and has been recently reclassified as a Category A Priority Pathogen by NIH. This elevated level of priority for CCHFV is due to its notably highly infectious nature and also reports of transmission by aerosol during the treatment of infected patients.
In collaboration with the University of Texas Medical Branch and the University of Cambridge, Hawaii Biotech is currently developing a CCHFV vaccine utilizing our proprietary vaccine production platform.
